A new version of CAR with improved antigen sensitivity

Xiaolei Su
Assistant Professor of Cell Biology
Yale University
Yale Innovation Summit 2023
Team

Xiaolei Su, PhD
Assistant Professor
Principal Investigator

Xinyan Zhang, MD
Postdoc
Leading scientist

Fawzaan Hashmi
Research Assistant Scientist

Sidi Chen, PhD
Associate Professor
Collaborator

Iris Isufi, MD
Associate Professor
Collaborator
Challenges

Current CARs have low antigen sensitivity:

• Failure to target low antigen-expressing cancer cells
• Frequent relapse during prolonged treatment of high antigen-expressing cancers because of antigen loss
Solution

Development of IDR CARs with enhanced antigen sensitivity towards blood and solid tumors

Impact

• Expand the target of CAR-T to low antigen-expressing cancers
• Reduce relapse frequency
Innovation

• IDR **broadly** improves antigen sensitivity of CARs targeting a variety of antigens

• IDR-induced **biomolecular condensation** promotes CAR-T activity

• IDR CAR can be combined with other strategies to improve CAR-T in an **additive or synergistic** manner
Data: IDR enhanced the killing of low antigen-expressing cancers
Usage of the fund

To evaluate the safety of IDR CAR-Ts in mouse models

Milestone

Identification of the IDR that achieves a balance between tumor eradication and tissue toxicity